Arginaut - IPF

  • Study Sponsor and Protocol Number: 
    AstraZeneca
  • Specialty:
    Pulmonary
  • Type:
    Investigational Drug
  • Inclusion:
    Age ≥ 40
    Diagnosis of Idiopathic Pulmonary Fibrosis based on chest high-resolution Computed Tomography (HRCT) within 12 months
  • Exclusion:
    Interstitial lung disease other than IPF